|
|
Article: A Comprehensive Big Pharma M&A Analysis to 2012 - Surveying the Growth Rate Landscape in This Company-by-Company Evaluation.
- Article from:
- Business Wire
- Article date:
- October 13, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/ed3063/big_pharma_ma_ana) has announced the addition of the "Big Pharma M&A Analysis to 2012 - Surveying the Growth Rate Landscape" report to their offering.
With sales growth rates expected to fall below their historic levels, Big Pharma must act to bolster its performance out to 2012 if it is to maintain the investment community's valuation of its stocks. One mechanism for plugging the sales growth rate gap and fulfilling investors growth imperative is M&A activity.
Scope
* Company-by-company evaluation of all Big Pharma-led M&A permutations within the ...